microRNA-99a acts as a tumor suppressor and is down-regulated in bladder cancer

[1]  G. Kristiansen,et al.  Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? , 2014, World Journal of Urology.

[2]  Wang Jing,et al.  Plasma microRNA profiles for bladder cancer detection. , 2013, Urologic oncology.

[3]  J Waxman,et al.  Circulating microRNAs as potential new biomarkers for prostate cancer , 2013, British Journal of Cancer.

[4]  Yibo Gao,et al.  MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma , 2013, Medical Oncology.

[5]  Hua Zhou,et al.  MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma , 2012, BMC Cancer.

[6]  B. Yan,et al.  Downregulation of microRNA 99a in oral squamous cell carcinomas contributes to the growth and survival of oral cancer cells. , 2012, Molecular medicine reports.

[7]  S. Yip,et al.  Expression of microRNAs in the urine of patients with bladder cancer. , 2012, Clinical genitourinary cancer.

[8]  Stefan Holdenrieder,et al.  MicroRNAs in Renal Cell Carcinoma: Diagnostic Implications of Serum miR-1233 Levels , 2011, PloS one.

[9]  G. Calin,et al.  MicroRNAs in body fluids—the mix of hormones and biomarkers , 2011, Nature Reviews Clinical Oncology.

[10]  J. Ellinger,et al.  Circulating microRNAs (miRNA) in serum of patients with prostate cancer. , 2011, Urology.

[11]  Jing Chen,et al.  MicroRNA Expression Signatures of Bladder Cancer Revealed by Deep Sequencing , 2011, PloS one.

[12]  Kazuya Kawahara,et al.  MiR‐96 and miR‐183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology , 2011, Cancer science.

[13]  Hua Zhao,et al.  A Pilot Study of Circulating miRNAs as Potential Biomarkers of Early Stage Breast Cancer , 2010, PloS one.

[14]  Takahiro Ochiya,et al.  Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis , 2010, Cancer science.

[15]  Jia Yu,et al.  miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. , 2010, Cancer research.

[16]  R. Lavker,et al.  MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. , 2010, Journal of hepatology.

[17]  Xi Chen,et al.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Saiful Miah,et al.  Distinct microRNA alterations characterize high- and low-grade bladder cancer. , 2009, Cancer research.

[19]  Jørgen Kjems,et al.  Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. , 2009, Cancer research.

[20]  M. Knowles,et al.  Molecular pathogenesis of bladder cancer , 2008, International Journal of Clinical Oncology.

[21]  Cicek Gercel-Taylor,et al.  MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. , 2008, Gynecologic oncology.

[22]  A. Harris,et al.  Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.

[23]  Thomas D. Schmittgen,et al.  Expression profiling identifies microRNA signature in pancreatic cancer , 2006, International journal of cancer.

[24]  T. Okanoue,et al.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.

[25]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[26]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[27]  Adel H Jebar,et al.  FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma , 2005, Oncogene.

[28]  J. Minna,et al.  Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. , 2001, Cancer research.

[29]  P. Green,et al.  Identification of p53 gene mutations in bladder cancers and urine samples. , 1991, Science.